Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Reaches ‘Modest’ Settlement With Georgia Over Price-Fixing Allegations

Israeli Giant Will Pay State $3.34m As Part Of Settlement

Executive Summary

Teva has made its third settlement with a US state following the Department of Justice’s price-fixing investigation, agreeing to pay Georgia $3.34m in exchange for the dismissal of all claims against the company and its affiliates.

You may also be interested in...



Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement

Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.

Teva Agrees To $420m Securities Settlement For Alleged Price Fixing

Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.

Teva State Settlement On Price-Fixing Could Be First Of Many

Teva has struck a $950,000 deal to settle US price-fixing litigation with the state of Mississippi, in what the firm anticipates could be the first of multiple settlements with individual US states.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel